Vijaya Diagnostic Centre Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Vijaya Diagnostic Centre Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹531
Per ShareLot Size
28 Shares
Minimum Investment
₹14,868
Issue Size
₹1,894.26 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Vijaya Diagnostic Centre Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
37.78%
Promoter Holding (Post-Issue)
32.78%
Issue Type
Book Building
ISIN
INE043W01024
About the Company
Vijaya Diagnostic Centre Limited is the largest comprehensive diagnostic chain in southern India, by revenue, and also one of the fastest-growing diagnostic chain by revenue, for fiscal year 2020. The Company offers an one-stop solution for pathology and radiology testing services to customers through its extensive operational network, which consists of 80 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh, and the National Capital Region and Kolkata.
Industry Overview
The Indian diagnostics market was valued at approximately Rs. 710 billion to Rs. 730 billion in FY 2021, and is projected to reach approximately Rs. 920 billion to Rs. 980 billion by FY 2023, driven by rise in health awareness and disposable incomes, increase in demand for better healthcare facilities and quality of care of individuals, and increase in spending on preventive and wellness. The diagnostics market in Telangana and Andhra Pradesh, in which the company has significant presence in, is projected to grow to approximately Rs. 120 billion to Rs. 130 billion by FY 2023.
Company History
Vijaya Diagnostic Centre Limited was incorporated as a private limited company with the name "Vijaya Diagnostic Centre Private Limited" on June 5, 2002 with a certificate of incorporation issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by its Shareholders at the EGM held on March 22, 2021 and the name of the Company was changed to Vijaya Diagnostic Centre Limited on March 26, 2021, and a fresh certificate of incorporation consequent on change of name was granted by the Registrar of Companies, Telangana at Hyderabad.
Products & Services
- The Company offers integrated diagnostic services to its customer through a network of diagnostic centres and reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in National Region and Kolkata
Growth Strategy
- Deepen Footprint in its core markets
- Leveraging its existing presence by focusing on setting up spoke centres and increasing home collection in existing catchment areas
- Continue to focus on providing customer centric services and offerings
- Expand in adjacent geographies and East India
- Supplement organic growth with selective acquisitions
Customer Base
The Company primarily derives all of its revenue from Walk-in customers
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial Public offer of equity shares of face value of Re. 1 each ("equity shares") of Vijaya Diagnostic Centre Limited ("company" or "issuer") for cash at a price of Rs. 531 per equity share ("offer price"), through an offer for sale of up to 35,688,064 equity shares aggregating to Rs. 1894.26 Crores ("offer") by the selling shareholders, comprising of 5,098,296 equity shares aggregating up to Rs. 270.61 Crores by Dr. S. Surendranath Reddy ("promoter selling shareholder"), 29,487,290 equity shares aggregating to Rs. 1565.13 Crores by Karakoram Limited and 1,102,478 equity shares aggregating to Rs. 58.52 Crores by Kedaara Capital Alternative Investment Fund - Kedaara Capital AIF 1 ("Karakoram Limited together with Kedaara Capital Alternative Investment Fund - Kedaara Capital AIF 1 referred to as "Investor Selling Shareholders") (Investor Sellling Shareholders together with the promoter selling shareholder referred to as the "selling shareholders"). This offer includes a reservation of 150,000 equity shares aggregating up to Rs. 7.19 crores (constituting up to 0.15% of the post-offer paid-up equity share capital) for purchase by eligible employees (the "employee reservation portion"). The offer less the employee reservation portion is hereinafter referred to as the "net offer". The offer and the net offer would constitute at least 35.00% and 34.85%, respectively, of the post-offer paid-up equity share capital. The Offer Price is 531 per Equity Share of face value of Rs. 1 each. A discount of Rs. 52 per Equity Share is being offered to Eligible Employees bidding in the Employees Reservation Portion. The Offer Price is Rs. 531 of the face value of the Equity Shares. Bids can be made for a minimum of 28 Equity Shares and in Multiples of 28 Equity Shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Largest and fastest growing diagnostic chain with dominant position in south India, well positioned to leverage the high growth in Indian diagnostics industry;
- Integrated diagnostics provider that offers one-stop solution at affordable price with focus on superior quality standards;
- High brand recall driving high individual consumer business share and customer stickiness;
- Strong technical capabilities, quality infrastructure and state of the art medical technology with strong IT infrastructure;
- Dedicated management team with significant industry experience
- The company business and prospects may be adversely affected if the company are unable to maintain and grow its brand name and brand image.
- Its business, financial condition and results of operations may be adversely affected by global health epidemics, including the recent COVID-19 outbreak, and the continuing effect of the same cannot be predicted.
- Any interruptions at its flagship centre and other diagnostic centres may affect its ability to process diagnostic tests, which in turn may adversely affect its business, results of operations and financial condition.
- Its operations are concentrated in south India, and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.
- The company depend on third-parties to provide the company its testing equipment and reagents, and any failure to continue to do so or recall of existing testing equipment and reagents could adversely affect its business, results of operations and financial condition.